Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 17,117 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Advanced Cancer
Interventions: AB801, Docetaxel; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Human Immunodeficiency Virus
Interventions: Provision of HIV self-test with Commitment and planning prompts, Provision of HIV self-test; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 19 Years and older
Enrollment: 1,479 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 7,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 267
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more

Conditions: Breast Cancer
Interventions: Cyclophosphamide, Docetaxel, Gemcitabine, Paclitaxel, Doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4,894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 12
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stuart, Florida + 9 more

Conditions: Crohn's Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 9 more

Conditions: Breast Neoplasms, Cancer of the Breast, Breast Cancer
Interventions: Gemcitabine, Trastuzumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 13
States / cities: Hot Springs, Arkansas • Pine Bluff, Arkansas • Redding, California + 10 more

Conditions: HIV Infections
Interventions: lopinavir/ritonavir plus maraviroc; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Knee Arthroscopy, Suture
Interventions: 3.0 monocryl suture, 3.0 nylon suture; Device
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Apixaban, Acetylsalicylic acid; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years and older
Enrollment: 6,421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 69
States / cities: Mobile, Alabama • Tucson, Arizona • Anaheim, California + 62 more

Conditions: Ketorolac, Joint Fusion
Interventions: great toe (1st metatarsophalangeal joint) fusion, IV Ketorolac, Ketorolac Pill, 5/325mg Oxycodone-Acetaminophen, Aspirin 81Mg Ec Tab; Procedure · Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Echocardiography, Blood Collection, Symptoms Questionnaire; Diagnostic Test · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2037
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108; Drug
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: Cognizance Biomarkers, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions: Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 201
States / cities: Phoenix, Arizona • Burbank, California • Concord, California + 138 more

Conditions: Parkinson's Disease, Sleep Fragmentation
Interventions: Deep Brain Stimulation; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • Philadelphia, Pennsylvania

Conditions: Tobacco Use Disorder
Interventions: Tolcapone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumors
Interventions: REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more

Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Interventions: Non-Interventional, Non-Interventional Follow-up; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 250µg; Drug
Lead sponsor: DBV Technologies; Industry
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more

Conditions: Cocaine Dependence, Cocaine Abuse
Interventions: Contingency Management; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Blood Pressure, High
Interventions: Ramipril and hydrochlorothiazide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more

Conditions: Lupus
Interventions: Coping skills and cognitive restructuring techniques, Educational training; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peanut Allergy
Interventions: AR101 powder provided in capsules, Placebo powder provided in capsules; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Search by objective public record fields.

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Plan and Pledge, HIV Self-testing in South Africa

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Sutures for Treatment of Knee Arthroscopy

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

Cardiotoxicity of Cancer Therapy (CCT)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)

Neural Substrates in Nicotine Withdrawal

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

Long Term Maintenance of Drug Abstinence

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

Improving Quality of Life for African American Female Adolescents With Lupus

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT